Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.40 |
---|---|
High | 20.00 |
Low | 18.40 |
Bid | 23.40 |
Offer | 24.20 |
Previous close | 15.20 |
Average volume | 53.57 |
---|---|
Shares outstanding | 17.59m |
Free float | 17.19m |
P/E (TTM) | -- |
Market cap | 388.32m USD |
EPS (TTM) | -0.8136 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 09:05 GMT.
More ▼
Press releases
- Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
- Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
- Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Rigel to Present at the 2024 Cantor Global Healthcare Conference
- Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
- Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
- Rigel to Participate in Upcoming September Investor Conferences
More ▼